Am J Psychiatry 156:756-760, May 1999
© 1999 American Psychiatric Association
Fluvoxamine Treatment of Social Phobia (Social Anxiety Disorder): A Double-Blind, Placebo-Controlled Study
Murray B. Stein, M.D.,
Abby J. Fyer, M.D.,
Jonathan R.T. Davidson, M.D.,
Mark H. Pollack, M.D., and
Brinda Wiita, Ph.D.
OBJECTIVE: The purpose of this study was to determine the efficacy of fluvoxamine for the treatment of social phobia (social anxiety disorder). METHOD: In a 12-week multicenter, double-blind, randomized, placebo-controlled trial, 92 patients with social phobia were treated with the selective serotonin reuptake inhibitor fluvoxamine; 91.3% of the patients had the generalized subtype of the disorder. The primary criterion for response was a rating of "much improved" or "very much improved" on the Clinical Global Impression of Improvement scale. Secondary response criteria were changes on three specialized rating scales for social phobia symptoms: the Brief Social Phobia Scale, the Social Phobia Inventory, and the Liebowitz Social Anxiety Scale. Psychosocial impairment was assessed in three domains (disruption of work, social life, and home/family life) by using the Sheehan Disability Scale. RESULTS: The mean daily dose of fluvoxamine was 202 mg (SD=86). At study end or with the last observation carried forward, within the evaluable subjects (N=86) there was a significantly higher proportion of responders in the fluvoxamine group (42.9%, N=18) than in the placebo group (22.7%, N=10). Similarly, fluvoxamine was superior to placebo on all social phobia rating scales at week 8 and beyond. Fluvoxamine also resulted in significantly greater decreases in measures of psychosocial disability than did placebo. Overall, fluvoxamine was well tolerated and safe. CONCLUSIONS: These findings indicate that fluvoxamine is efficacious in the pharmacologic management of serious forms of social phobia.
This article has been cited by other articles:
|
|
|
|
 
References
PsychiatryOnline CME,
May 1, 2007;
2007(1):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
D. W. Hedges, B. L. Brown, D. A. Shwalb, K. Godfrey, and A. M. Larcher
The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials
J Psychopharmacol,
January 1, 2007;
21(1):
102 - 111.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Kasper, D. J. Stein, H. Loft, and R. Nil
Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study
The British Journal of Psychiatry,
March 1, 2005;
186(3):
222 - 226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Liebowitz, A. J. Gelenberg, and D. Munjack
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Arch Gen Psychiatry,
February 1, 2005;
62(2):
190 - 198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Barnett, M. L. Kramer, C. D. Casat, K. M. Connor, and J. R. T. Davidson
Efficacy of olanzapine in social anxiety disorder: a pilot study
J Psychopharmacol,
July 1, 2002;
16(4):
365 - 368.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. M. Simon, M. W. Otto, N. B. Korbly, P. M. Peters, D. C. Nicolaou, and M. H. Pollack
Quality of Life in Social Anxiety Disorder Compared With Panic Disorder and the General Population
Psychiatr Serv,
June 1, 2002;
53(6):
714 - 718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Schneider and J. L. Levenson
Update in Psychiatry
Ann Intern Med,
February 19, 2002;
136(4):
293 - 301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Stein, J. Sareen, S. Hami, and J. Chao
Pindolol Potentiation of Paroxetine for Generalized Social Phobia: A Double-Blind, Placebo-Controlled, Crossover Study
Am J Psychiatry,
October 1, 2001;
158(10):
1725 - 1727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Grossman, F. H. Wilhelm, I. Kawachi, and D. Sparrow
Gender Differences in Psychophysiological Responses to Speech Stress Among Older Social Phobics:: Congruence and Incongruence Between Self-Evaluative and Cardiovascular Reactions
Psychosom Med,
September 1, 2001;
63(5):
765 - 777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. BLOMHOFF, T. TANGEN HAUG, K. HELLSTROM, I. HOLME, M. HUMBLE, H. P. MADSBU, and J. E. WOLD
Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia
The British Journal of Psychiatry,
July 1, 2001;
179(1):
23 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Oosterbaan, A. J. L. M. van Balkom, P. Spinhoven, and R. van Dyck
The placebo response in social phobia
J Psychopharmacol,
May 1, 2001;
15(3):
199 - 203.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Van Ameringen, R. M. Lane, J. R. Walker, R. C. Bowen, P. R. Chokka, E. M. Goldner, D. G. Johnston, Y.-J. Lavallee, S. Nandy, J. C. Pecknold, et al.
Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
February 1, 2001;
158(2):
275 - 281.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. V. Mendlowicz and M. B. Stein
Quality of Life in Individuals With Anxiety Disorders
Am J Psychiatry,
May 1, 2000;
157(5):
669 - 682.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. M. CONNOR, J. R. T. DAVIDSON, L. E. CHURCHILL, A. SHERWOOD, R. H. WEISLER, and E. FOA
Psychometric properties of the Social Phobia Inventory (SPIN): New self-rating scale
The British Journal of Psychiatry,
April 1, 2000;
176(4):
379 - 386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Hidalgo and J. R. T. Davidson
Selective serotonin reuptake inhibitors in post-traumatic stress disorder
J Psychopharmacol,
January 1, 2000;
14(1):
70 - 76.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Ment. Health,
November 1, 1999;
2(4):
104 - 104.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
